Vaccination with recombinant Mycobacterium avium subsp. paratuberculosis proteins induces differential immune responses and protects calves against infection by oral challenge

Kumanan, K.; Sung-Un, Park; McDonough, Sean P.; Stehman, Susan M.; Akey, Bruce; Huntley, John F.; Wong, Susan J.; Chang, Ching Hsun; Chang, Yung-Fu

doi:10.1016/j.vaccine.2008.01.015

Cited by 46 publications

(38 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following challenge, attempts were made to isolate M. avium subsp. paratuberculosis organisms from feces by using Herald's egg yolk (HEY) medium (Becton, Dickinson and Co., Sparks, MD) following standard Cornell University protocols (34,35). Fecal samples were collected from all animals at 2, 4, 6, 8, and 10 days after challenge and every month thereafter for M. avium subsp.…”

Section: Animalsmentioning

confidence: 99%

Evaluation of a Mycobacterium avium subsp. paratuberculosisleuDMutant as a Vaccine Candidate against Challenge in a Caprine Model

Faisal

Chen

Yan

et al. 2013

Clin Vaccine Immunol

Self Cite

View full text Add to dashboard Cite

f Johne's disease (JD) is prevalent worldwide and has a significant impact on the global agricultural economy. In the present study, we evaluated the protective efficacy of a leuD (⌬leud) mutant and gained insight into differential immune responses after challenge with virulent M. avium subsp. paratuberculosis in a caprine colonization model. The immune response and protective efficacy were compared with those of the killed vaccine Mycopar. In vitro stimulation of peripheral blood mononuclear cells with johnin purified protein derivative showed that Mycopar and ⌬leuD generated similar levels of gamma interferon (IFN-␥) but significantly higher levels than unvaccinated and challenged phosphate-buffered saline controls. However, only with ⌬leuD was the IFN-␥ response maintained. Flow cytometric analysis showed that the increase in IFN-␥ correlated with proliferation and activation (increased expression of CD25) of CD4, CD8, and ␥␦T cells, but this response was significantly higher in ⌬leuD-vaccinated animals at some time points after challenge. Both Mycopar and ⌬leuD vaccines upregulated Th1/proinflammatory and Th17 cytokines and downregulated Th2/anti-inflammatory and regulatory cytokines at similar levels at almost all time points. However, significantly higher levels of IFN-␥ (at weeks 26 and 30), interleukin-2 (IL-2; week 18), IL-1b (weeks 14 and 22), IL-17 (weeks 18 and 22), and IL-23 (week 18) and a significantly lower level of IL-10 (weeks 14 and 18) and transforming growth factor ␤ (week 18) were detected in the ⌬leuD-vaccinated group. Most importantly, ⌬leuD elicited an immune response that significantly limited colonization of tissues compared to Mycopar upon challenge with wild-type M. avium subsp. paratuberculosis. In conclusion, the ⌬leuD mutant is a promising vaccine candidate for development of a live attenuated vaccine for JD in ruminants.

show abstract

Section: Animalsmentioning

confidence: 99%

Evaluation of a Mycobacterium avium subsp. paratuberculosisleuDMutant as a Vaccine Candidate against Challenge in a Caprine Model

Faisal

Chen

Yan

et al. 2013

Clin Vaccine Immunol

Self Cite

View full text Add to dashboard Cite

show abstract

“…MAP exposure, which leads to disease, occurs primarily in utero and/or in newborns. 2,[4][5][6][7][8][9][10][11][12] As Johne disease has become an increasingly worldwide problem, due in part to the absence of preventive vaccine/drug or curative treatments, 13 including the partially protective, MAP subunit vaccine, 14 awareness as to what role, if any, animals play in the transmission of MAP to humans is being raised. [15][16][17][18][19][20][21] This concern arises from the apparent specific association of MAP with Crohn disease, even though a role (etiology agent?)…”

Section: Introductionmentioning

confidence: 99%

Assessment ofDietziasubsp.C79793-74for treatment of cattle with evidence of paratuberculosis

Click

Kampen

2010

Virulence

View full text Add to dashboard Cite

“…Several Th1 antigens have been identified by genomic and proteomic analysis: the antigen 85 complex proteins (A, B and C) and superoxide dismutase (Shin et al 2005); Hsp65 and Hsp70 (Koets et al 1999); lipoprotein LprG ( (Rigden et al 2006); PPE family proteins MAP1518 and MAP3184 (Nagata et al 2005). Only few of these have been tested in cattle, the target species, namely: the antigen 85 complex proteins together with superoxide dismutase and heat shock protein 70 (Koets et al 2006;Kathaperumal et al 2008). …”

Section: Paratuberculosis Vaccine Developmentmentioning

confidence: 99%

Bovine paratuberculosis: recent advances in vaccine development

Santema

Rutten

Koets

2011

Veterinary Quarterly

View full text Add to dashboard Cite

Bovine paratuberculosis is a highly prevalent chronic infection of the small intestine in cattle, caused by Mycobacterium avium subspecies paratuberculosis. Current control strategies based on test-and-cull and biosecurity measures do not suffice in lowering the prevalence of paratuberculosis in an adequate manner. Therefore, control programmes are in need of an effective vaccine, but at the moment no vaccine is registered for use in cattle in the European Union. This review provides a brief overview of the microbiology, epidemiology and immunology of bovine paratuberculosis, and focuses on recent advances in the development of vaccines against paratuberculosis.

show abstract

Vaccination with recombinant Mycobacterium avium subsp. paratuberculosis proteins induces differential immune responses and protects calves against infection by oral challenge

Cited by 46 publications

References 27 publications

Evaluation of a Mycobacterium avium subsp. paratuberculosisleuDMutant as a Vaccine Candidate against Challenge in a Caprine Model

Evaluation of a Mycobacterium avium subsp. paratuberculosisleuDMutant as a Vaccine Candidate against Challenge in a Caprine Model

Assessment ofDietziasubsp.C79793-74for treatment of cattle with evidence of paratuberculosis

Bovine paratuberculosis: recent advances in vaccine development

Contact Info

Product

Resources

About